We know that nongenetic forms of resistance to therapies such as Menin and BET inhibition in AML utilize mechanisms including enhancer switching and transcriptional plasticity to maintain the expression of oncogenes [97]. This evidence concerns the gene DNER and acute myeloid leukemia.